Wei‐Fen Xie

6.5k total citations
116 papers, 4.3k citations indexed

About

Wei‐Fen Xie is a scholar working on Molecular Biology, Hepatology and Epidemiology. According to data from OpenAlex, Wei‐Fen Xie has authored 116 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Molecular Biology, 49 papers in Hepatology and 44 papers in Epidemiology. Recurrent topics in Wei‐Fen Xie's work include Liver Disease Diagnosis and Treatment (33 papers), Liver physiology and pathology (32 papers) and MicroRNA in disease regulation (11 papers). Wei‐Fen Xie is often cited by papers focused on Liver Disease Diagnosis and Treatment (33 papers), Liver physiology and pathology (32 papers) and MicroRNA in disease regulation (11 papers). Wei‐Fen Xie collaborates with scholars based in China, United States and Spain. Wei‐Fen Xie's co-authors include Yue-Xiang Chen, Beifang Ning, Jin Ding, Chuan Yin, Xin Zeng, Hongyang Wang, Xin Zhang, Xing Deng, Yong Lin and Jian Shi and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Gastroenterology.

In The Last Decade

Wei‐Fen Xie

110 papers receiving 4.3k citations

Peers

Wei‐Fen Xie

HEPAT

EPIDE

ONCOL

Jens U. Marquardt Germany

Satoshi Shimizu Japan

Hayato Hikita Japan

Olivier Govaere Belgium

Frank Dombrowski Germany

Le‐Xing Yu China

Hong‐Yang Wang China

Jesús M. Bañales Spain

Véronique Barbu France

Henning Schulze‐Bergkamen Germany

Jens U. Marquardt Germany

Wei‐Fen Xie

2.1k ×1.0

1.5k ×1.2

HEPAT

1.0k ×1.0

EPIDE

1.1k ×1.1

1.1k ×1.3

ONCOL

Citations per year, relative to Wei‐Fen Xie Wei‐Fen Xie (= 1×) peers Jens U. Marquardt

Countries citing papers authored by Wei‐Fen Xie

Since Specialization

Citations

This map shows the geographic impact of Wei‐Fen Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei‐Fen Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei‐Fen Xie more than expected).

Fields of papers citing papers by Wei‐Fen Xie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei‐Fen Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei‐Fen Xie. The network helps show where Wei‐Fen Xie may publish in the future.

Co-authorship network of co-authors of Wei‐Fen Xie

This figure shows the co-authorship network connecting the top 25 collaborators of Wei‐Fen Xie. A scholar is included among the top collaborators of Wei‐Fen Xie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wei‐Fen Xie. Wei‐Fen Xie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Keqi, et al.. (2025). Endothelial Tgfbr2 Deficiency Ameliorate Liver Fibrosis Through Regulating Angiocrine Signalling and Macrophage Accumulation. Liver International. 45(9). e70227–e70227.

Ding, Chen‐Hong, Binghe Xu, Hui Qian, et al.. (2025). PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma. Cell Death and Disease. 16(1). 158–158. 11 indexed citations

Huang, Chenkai, Hui Qian, Chen‐Hong Ding, et al.. (2025). Positive feedback between arginine methylation of YAP and methionine transporter SLC43A2 drives anticancer drug resistance. Nature Communications. 16(1). 87–87. 6 indexed citations

Qian, Hui, Chen‐Hong Ding, Fang Liu, et al.. (2024). SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors. Signal Transduction and Targeted Therapy. 9(1). 96–96. 8 indexed citations

Yu, Peng, Wenping Xu, Chen‐Hong Ding, et al.. (2024). Tripartite motif 8 promotes the progression of hepatocellular carcinoma via mediating ubiquitination of HNF1α. Cell Death and Disease. 15(6). 416–416. 2 indexed citations

Deng, Juan, et al.. (2024). SOX9 Overexpression Ameliorates Metabolic Dysfunction-associated Steatohepatitis Through Activation of the AMPK Pathway. Journal of Clinical and Translational Hepatology. 0(0). 0–0. 1 indexed citations

Zhu, Changpeng, Shuqing Liu, Keqi Wang, et al.. (2024). Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension. Gastroenterology. 167(5). 993–1007. 3 indexed citations

Zeng, Xin, Jiajun Yu, Lifen Wang, et al.. (2023). Skeletal muscle alterations indicate poor prognosis in cirrhotic patients: a multicenter cohort study in China. Hepatology International. 18(2). 673–687. 7 indexed citations

Fang, Jing‐Yuan, Yunsheng Yang, & Wei‐Fen Xie. (2023). Chinese expert consensus on the application of live combined Bifidobacterium, Lactobacillus, and Enterococcus powder/capsule in digestive system diseases (2021). Journal of Gastroenterology and Hepatology. 38(7). 1089–1098. 14 indexed citations

10.

Xu, Wenping, Jinpei Liu, Shuqing Liu, et al.. (2023). A BBS4 mutation causes autosomal dominant polycystic liver disease. Genes & Diseases. 11(1). 72–75. 1 indexed citations

11.

Huang, Ru Chih C., Xin Zhang, Jordi Gracia‐Sancho, & Wei‐Fen Xie. (2022). Liver regeneration: Cellular origin and molecular mechanisms. Liver International. 42(7). 1486–1495. 37 indexed citations

12.

Zeng, Xin, Jiajun Yu, Lifen Wang, et al.. (2021). Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China. Journal of Cachexia Sarcopenia and Muscle. 12(6). 1948–1958. 92 indexed citations

13.

Xu, Wenping, Kai Ding, Chen‐Hong Ding, et al.. (2021). Deletion ofSox9in the liver leads to hepatic cystogenesis in mice by transcriptionally downregulatingSec63. The Journal of Pathology. 254(1). 57–69. 6 indexed citations

14.

Xu, Wenping, Jinpei Liu, Jifeng Feng, et al.. (2019). miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy. Gut. 69(7). 1309–1321. 88 indexed citations

15.

Xiang, Daimin, Wen Sun, Beifang Ning, et al.. (2017). The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis. Gut. 67(9). 1704–1715. 181 indexed citations

16.

Zhao, Hongxin & Wei‐Fen Xie. (2016). [Current status of the treatment of drug-induced liver injury].. PubMed. 24(11). 804–806.

17.

Wen, Wen, Jin Ding, Wen Sun, et al.. (2010). Suppression of Cyclin D1 by Hypoxia-Inducible Factor-1 via Direct Mechanism Inhibits the Proliferation and 5-Fluorouracil–Induced Apoptosis of A549 Cells. Cancer Research. 70(5). 2010–2019. 69 indexed citations

18.

Ning, Beifang, Jin Ding, Chuan Yin, et al.. (2010). Hepatocyte Nuclear Factor 4α Suppresses the Development of Hepatocellular Carcinoma. Cancer Research. 70(19). 7640–7651. 194 indexed citations

19.

Zeng, Xin, Yong Lin, Sheng Xia, et al.. (2010). Combination of taurine with silybin meglumine in treatment of patients with non-alcohlic steatohepatitis. Zhonghua xiaohua zazhi. 30(7). 441–443. 1 indexed citations

20.

Chen, Yue-Xiang, Siwen Chen, Xingrong Zhang, et al.. (2005). [Inhibition of proliferation of hepatic stellate cells by taurine is mediated via regulating cell cycle proteins].. PubMed. 13(8). 571–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact